This page shows what was measured, who it was measured in, and what that does not settle.
What Prednisolone does in the body
Your adrenal glands make a hormone called cortisol that tells cells to stop producing inflammatory proteins.
Prednisolone is a manufactured version of that hormone, altered so it lasts longer and acts more on inflammation than on salt and water balance. Once inside a cell it binds a receptor that travels into the nucleus, settles on the DNA, and silences the genes that make the signals of inflammation. Because that receptor sits in nearly every cell in the body, the drug cannot be aimed: the same switch that quietens a swollen joint also thins bone, raises blood sugar and blunts the response to infection.
Why people take it. Inflammation and overactive immune responses, across a very wide range of conditions
What happened in people
Complete facial recovery in 83.0% against 63.6% at three months in Bell’s palsy, P<0.001, in a placebo-controlled factorial trial
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The recorded finding that sits closest to something a person would notice. Written into the record, not signed off, and it carries no population or interval.
That the standard steroid equivalence table transfers harm as well as potency — it was built from anti-inflammatory bioassay, and adrenal suppression follows half-life instead
Where it acts
The cytoplasm and then the nucleus of almost every nucleated cell in the body — the glucocorticoid receptor is not tissue-restricted, and that is the whole story of this drug
Kind of result
The kind of result is not recorded
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 9PHQ9Y1OLM · read 2026-08-29
Its recorded molecular formula is C21H27Na2O8P, weighing 484.39.
US prescribing information · 1e379543-c4cf-4e72-953b-db15b7f0c2a1 · read 2026-08-30
Where each sentence above came from
A person wrote this explanation into the record, with the studies named in the path below.
The recorded use, written for a reader without medical training. Not signed off.
A limit recorded against this substance. Not signed off as a reviewed claim.
The four opening statements run to 138 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Stand-in result
A stand-in result is a number measured because the real result takes too long.
A picture of it, and where the picture fails
It is like judging a journey by the speedometer rather than by arriving.
Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.
What people get wrong. A stand-in result is often reported as the result itself.
A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.
Randomisation
Randomisation means chance decides who gets which treatment.
A picture of it, and where the picture fails
It is like a coin toss deciding the groups.
Where that stops being true. A coin toss is fair once. Fairness here comes from doing it for everyone.
What people get wrong. It is thought to make groups identical. It makes them similar on average, including on things nobody measured.
Allocation of participants to arms by a chance process, so that unmeasured factors are balanced in expectation.
Confidence interval
A confidence interval is the range the true answer is likely to sit in.
A picture of it, and where the picture fails
It is like a weather forecast giving a range rather than one number.
Where that stops being true. A forecast range covers tomorrow. This one covers what the study could resolve.
What people get wrong. The middle number is read as the answer. A range crossing zero means no change is still possible.
An interval estimate that would contain the true parameter in a stated proportion of repeated studies.
Pathway
A pathway is a chain of steps inside a cell, each one setting off the next.
A picture of it, and where the picture fails
A pathway is like a row of dominoes.
Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.
What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.
An ordered series of molecular interactions producing a defined cellular change.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
Complete recovery of facial function on the House-Brackmann scale at 3 months
83.0% with prednisolone against 63.6% without, P<0.001
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Final outcomes were assessed in 496 of 551 randomised, a 10% loss. The trial reported no serious adverse events, but a 10-day course is too short to detect the harms this class is known for.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral solution, oral tablet, orally disintegrating tablet, ophthalmic suspension and emulsion, and injectable sodium phosphate and acetate salts
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
Radiographic progression of hand joint damage by Larsen index at one and two years, and new erosions in previously unaffected hands
✓ The study showed what it set out to show
Who was studied
ARC Low-Dose Glucocorticoid Study (Kirwan 1995)
How many people
128
Study design
Randomised, double-blind, placebo-controlled
Compared against
A dummy treatment
Kind of result
A number that stands in for health
What was found
Larsen score rose 0.72 units against 5.37 units, P=0.004; new erosions 22.1% against 45.6%, difference 23.5 percentage points (95% CI 5.9 to 40.7), P=0.007
Repeated elsewhere
Replicated
What this does not prove. Meeting one endpoint in one population does not carry to other goals or other people.
The limits of this study, and where it came from
Main limit. Radiographic analysis rested on 106 of 128 randomised patients. The trial ran for two years, which is long enough to measure erosion and too short to measure the fracture risk the same treatment creates.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral solution, oral tablet, orally disintegrating tablet, ophthalmic suspension and emulsion, and injectable sodium phosphate and acetate salts
Interval reported. 95% CI 5
Written into the record, not signed off as a reviewed claim.
Odds ratio 0.72 (95% CI 0.52 to 1.01), P=0.06 — did not reach significance; no difference at 90 days or 1 year
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. Serious infections occurred in 13% of prednisolone-treated patients against 7% of those not treated with it, P=0.002. That harm is in the abstract and is routinely omitted when the 28-day point estimate is quoted as if it were positive.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral solution, oral tablet, orally disintegrating tablet, ophthalmic suspension and emulsion, and injectable sodium phosphate and acetate salts
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
13.9 hours on placebo against 11.0 hours on prednisolone; ratio of geometric means 0.90 (95% CI 0.77 to 1.05)
Repeated elsewhere
Replicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral solution, oral tablet, orally disintegrating tablet, ophthalmic suspension and emulsion, and injectable sodium phosphate and acetate salts
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
Hazard ratio 0.87 (95% CI 0.65 to 1.17), log-rank P=0.28
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. The extended-course group received about 900 mg/m2 more prednisolone in the trial and no less afterwards: total post-trial dose was 6,674 mg against 5,475 mg, P=0.07.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral solution, oral tablet, orally disintegrating tablet, ophthalmic suspension and emulsion, and injectable sodium phosphate and acetate salts
Interval reported. 95% CI 0
Written into the record, not signed off as a reviewed claim.
RNAWiki holds 5 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What happened in people◇Read from sources, not yet reviewed
How close this is to real life
The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.
■Living longer, or avoiding a major eventEvidence recorded. Death, a heart attack, a stroke, a hospital stay.14 registered measures of this kind. No reviewed result.
□What a body can do day to dayNo evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
□Measured performanceNo evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
□Symptoms and quality of lifeNo evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.No registered study measures this.
■A number that stands in for healthEvidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.1 registered measure of this kind.
■A step measured inside a personEvidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
■AnimalsEvidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse, Rat, Dog. A result in animals says what to test next. It does not say what happens in people.
■Cells in a dishEvidence recorded. Cells or chemistry on a bench, far from a whole body.Stored mechanism abstracts describe steps measured in cells or tissue.
□A guess from softwareNo evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.
Higher on these steps means closer to something a person would feel. It does not mean better done.
What it changes in the body◇Read from sources, not yet reviewed
The path through the body
From what a person takes to what changes. A solid line is a step measured in people. A dashed line is a step nobody has measured that way.
Start
Prednisolone
What a person takes: Oral solution, oral tablet, orally disintegrating tablet, ophthalmic suspension and emulsion, and injectable sodium phosphate and acetate salts.
The measurement behind this step
Absorbed rapidly and completely from the gut, with peak concentrations within one to two hours. The sodium phosphate salt is water-soluble and used for injection and for oral solution; the acetate salt is a poorly soluble depot for intra-articular and ophthalmic use. Ophthalmic formulations exist because the eye is one of the few places a glucocorticoid can be delivered locally at high concentration with limited systemic exposure.
Getting in
Swallowed or injected, and already active
Unlike its close relative prednisone, prednisolone does not need the liver to switch it on. It is the working form from the moment it is absorbed, which is why it is preferred when liver function cannot be relied on.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Prednisolone is the 11-beta-hydroxy species. Prednisone is its 11-keto prodrug and has no intrinsic receptor affinity until 11-beta-hydroxysteroid dehydrogenase type 1, largely hepatic, reduces it. Prednisolone is extensively protein bound, principally to transcortin at low concentrations and to albumin once transcortin saturates, which gives it non-linear kinetics across the clinical range.
Steroids are greasy enough to cross a cell membrane without a transporter or a receptor on the surface. There is no gate to select which cells receive the drug, which is the reason its effects are body-wide.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Passive diffusion across the lipid bilayer, driven by the logP of about 1.9 held on this record. Intracellular access is modulated rather than gated: the efflux pump P-glycoprotein exports some glucocorticoids, and 11-beta-hydroxysteroid dehydrogenase type 2 in kidney and colon inactivates cortisol locally to protect the mineralocorticoid receptor — a protection prednisolone partly evades.
It frees a receptor that was being held in reserve
Waiting in the cytoplasm is a receptor clamped in a complex of chaperone proteins. When prednisolone binds, the clamp releases and the receptor is free to move.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
The unliganded glucocorticoid receptor (NR3C1) is held in an inactive multiprotein complex with HSP90, HSP70, p23 and an immunophilin, usually FKBP51. Ligand binding triggers exchange of FKBP51 for FKBP52, which recruits dynein and licenses nuclear import through the receptor’s two nuclear localisation signals.
The receptor enters the nucleus and rewrites which genes are read
The freed receptor travels into the nucleus and does two things at once: it switches some genes on by landing directly on the DNA, and it switches others off by grabbing the proteins that would have turned them on.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Homodimers bind glucocorticoid response elements to transactivate genes including TSC22D3 (GILZ), NFKBIA, DUSP1 and ANXA1. Monomeric receptor transrepresses by tethering to NF-kappaB p65 and to AP-1, and by recruiting histone deacetylase 2 to their promoters, suppressing IL-1, IL-2, IL-6, TNF-alpha, COX-2 and inducible nitric oxide synthase. Transactivation is thought to carry most of the metabolic harm and transrepression most of the anti-inflammatory benefit, which is the premise of the dissociated-steroid programmes that have so far produced no marketed drug.
Inflammation falls within hours, and keeps falling for days
Because the effect works through gene transcription rather than by blocking a single molecule, it takes a few hours to appear and then persists after the drug itself has been cleared.
──Measured in people. Written by a person from the study named beside the step. Not signed off as a reviewed claim.
The measurement behind this step
The plasma half-life is 2 to 4 hours but the biological half-life is 12 to 36 hours, because the endpoint is a changed transcriptional programme rather than an occupied receptor. Measured downstream effects include lymphocyte redistribution out of the circulation within hours, suppressed eosinophil counts, reduced capillary permeability and inhibited phospholipase A2 activity through induced annexin A1.
The same receptor is in bone, muscle, pancreas and the adrenal feedback loop
There is no version of this mechanism that only affects the inflamed tissue. The receptor sits in bone-building cells, in muscle, in the liver and in the gland that makes your own cortisol, and the drug acts on all of them at once.
╌╌Described, with no measurement named. No measurement is named for this step, so it is drawn as an unconfirmed link.
The measurement behind this step
Glucocorticoid receptor activation in osteoblasts suppresses Wnt signalling and increases osteoclast lifespan, in skeletal muscle induces atrophy through FOXO and myostatin, in liver induces gluconeogenic enzymes, and at the pituitary suppresses proopiomelanocortin transcription and therefore ACTH, causing adrenal atrophy. Fracture risk rises within 3 to 6 months of starting, and hypothalamic-pituitary-adrenal recovery after a prolonged course can take months.
No suggested links are held for this record, so nothing is hidden from this path.
What we know
The record describes 6 steps from taking it to an effect in a person.
How we know it
Each step names the study behind it in the technical detail beside it.
What this does not prove
A change inside the body is a reason to look. It is not a result in a person.
Why it matters
A reader can see exactly where the chain stops being measured in people.
What we still do not know
No reviewed claim binds any of these steps to a named population.
What it would be like to take◇Read from sources, not yet reviewed
Felt, measured, or meaningful
Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.
Felt
Things a person could notice without a test.
No registered study measured anything of this kind.
Measured
Things only a test, a scale or a device shows.
creatinine clearance rate
Meaningful
Things that change how a life goes, not only a number.
event free survival
event free survival after first randomization
disease free survival after second and third randomization
event free survival at 3 4 years after diagnosis
disease free survival by routine imaging
rate of complete remission
disease free survival
remission rate
remission duration
overall survival
and 4 more.
A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.
Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.
Measured, but not felt. A number moves. The person notices nothing. Both can be true.
Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.
Matters, but takes years. The result that counts may take longer than anyone would keep watching.
Names that fit none of the three (25)
toxicity
renal function
an acr20 response
glomerular filtration rate from baseline to month 12
proteinuria
side effects
renal function at month 12 post transplantation
therapeutic failure rate
50 improvement of basdai after 14 days of treatment
composite efficacy endpoints 12 month analysis
forced expiratory volume in one second
transplantation
disease activity index
cortisol levels
composite efficacy failure at 12 months
admission to the intensive care
readmission to the hospital because of copd
the necessity to intensify pharmacologic treatment
improvement in the appearance of hemangioma
cataracts on ophthalmologist s examination
These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
People with asthma flares, inflammatory bowel disease, rheumatoid arthritis, nephrotic syndrome, autoimmune skin disease, transplant rejection, some cancers, and adrenal insufficiency, where it is replacing a hormone rather than suppressing anything.
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The efficacy and safety of prednisolone in the pediatric population are based on the well-established course of effect of corticosteroids, which is similar in pediatric and adult populations.”
US prescribing information · 1e379543-c4cf-4e72-953b-db15b7f0c2a1 · read 2026-08-30
On older people, the label states: “No overall differences in safety or effectiveness were observed between elderly subjects and younger subjects, and other reported clinical experience with prednisolone has not identified differences in responses between the elderly and younger patients.”
US prescribing information · 1e379543-c4cf-4e72-953b-db15b7f0c2a1 · read 2026-08-30
On people who are pregnant, the label states: “5.10 Embryo-Fetal Toxicity Prednisolone can cause fetal harm when administered to a pregnant woman.”
US prescribing information · 1e379543-c4cf-4e72-953b-db15b7f0c2a1 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk Summary Prednisolone is present in human milk.”
US prescribing information · 1e379543-c4cf-4e72-953b-db15b7f0c2a1 · read 2026-08-30
Where the result stopped carrying
STOPAH missed its primary endpoint in the largest alcoholic hepatitis trial ever conducted, and nearly doubled serious infections
A five-day course did not shorten hospital stay for preschool children with viral wheeze in 687 analysed patients
Doubling the initial course length in childhood nephrotic syndrome changed neither time to relapse nor any secondary outcome
Dissociated steroids, designed to keep the transrepression and drop the transactivation, have been pursued for thirty years and none has been approved
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied for a different goal
The studies measured something else entirely.
On this record: Some registered studies measured things that match no goal on this page.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral solution, oral tablet, orally disintegrating tablet, ophthalmic suspension and emulsion, and injectable sodium phosphate and acetate salts
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S3.
No source is stored against this line.
What is in the pack
Absorbed rapidly and completely from the gut, with peak concentrations within one to two hours. The sodium phosphate salt is water-soluble and used for injection and for oral solution; the acetate salt is a poorly soluble depot for intra-articular and ophthalmic use. Ophthalmic formulations exist because the eye is one of the few places a glucocorticoid can be delivered locally at high concentration with limited systemic exposure.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Regulatory records are listed in the technical disclosure at the foot of this page.
# Counted from records
Where this came from
A count of rows RNAWiki holds. It describes our records, not your body.
Register entries are stored per jurisdiction and shown with their dates.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take◇Read from sources, not yet reviewed
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
·Worth asking a clinician aboutWritten into the record from the studies named on this page
The label warns of adrenal suppression on withdrawal, increased susceptibility to and masking of infection, reactivation of latent tuberculosis, osteoporosis and fracture, hyperglycaemia, hypertension, fluid retention, cataract and glaucoma, growth suppression in children, peptic ulceration in combination with NSAIDs, and psychiatric disturbance including mania and depression. Live vaccines are contraindicated at immunosuppressive exposure. In a nationwide cohort of 1,548,945 adults, sepsis, venous thromboembolism and fracture rates all rose within 30 days of even a short course, and the rise persisted below a 20 mg prednisone-equivalent daily dose.
Nobody counted how many people took this and were fine, so this cannot be turned into a rate.
These are reports people sent to a regulator. They do not show the medicine caused the reaction.
Nobody counted how many people took the medicine and reported nothing.
The same event can be reported more than once, and many reports are incomplete.
News coverage, lawsuits and new warnings change how often people report.
A count is not a rate and not a risk.
Prednisolone appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 28066 reaction mentions were counted. One report can name several reactions.
open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral solution, oral tablet, orally disintegrating tablet, ophthalmic suspension and emulsion, and injectable sodium phosphate and acetate salts
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
The sodium phosphate salt is water-soluble and used for injection and for oral solution; the acetate salt is a poorly soluble depot for intra-articular and ophthalmic use. Ophthalmic formulations exist because the eye is one of the few places a glucocorticoid can be delivered locally at high concentration with limited systemic exposure.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on which forms are sold and how they compare.
No source is stored against this line.
What is recorded as being sold
101 products list this as an active ingredient in the United States drug directory. 99 of them contain it and nothing else.
FDA National Drug Code directory · 46439-8773 · read 2026-08-29
They are sold as powder, solution, solution/ drops, suspension/ drops, syrup and tablet, taken ophthalmic and oral.
FDA National Drug Code directory · 46439-8773 · read 2026-08-29
The regulator's established pharmacologic class for it is corticosteroid hormone receptor agonists [moa] and corticosteroid [epc].
FDA National Drug Code directory · 46439-8773 · read 2026-08-29
50 published labels name it as an active ingredient. 48 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · a0d74ae0-7b2d-4d36-9211-c76f5063b5a9 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · a0d74ae0-7b2d-4d36-9211-c76f5063b5a9 · read 2026-08-29
Orapred ODT is oral at 3 DOSAGE FORMS AND STRENGTHS Orally disintegrating tablets: 10 mg prednisolone (as 13.4 mg prednisolone sodium phosphate) 15 mg prednisolone (as 20.2 mg prednisolone sodium phosphate) 30 mg prednisolone (as 40.3 mg pred…, recorded as fda label in effect 2025-06-03 in the United States.
US prescribing information · 1e379543-c4cf-4e72-953b-db15b7f0c2a1 · read 2026-08-30
Recorded price in US: 0.1047–2.43026 USD per one millilitre, across 15 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Recorded price in US: 8.61401 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 3 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Prednisolone studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
Claims that go past the evidence
Things said about this substance that sound reasonable, and the exact step that is missing between the evidence and the claim.
✗Goes past the evidence
That the standard steroid equivalence table transfers harm as well as potency — it was built from anti-inflammatory bioassay, and adrenal suppression follows half-life instead
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That a short course is a safe course; the harm signal persists below a 20 mg prednisone-equivalent daily dose
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That the 28-day point estimate in alcoholic hepatitis represents a benefit, when the confidence interval crosses one and the 90-day and one-year results are flat
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
✗Goes past the evidence
That because glucocorticoids work fast in a flare, longer courses work better — three separate trials on this page found extending or adding a course changed nothing
Why it sounds right. It follows from something real on this page: a body step, an animal result or a related finding.
The missing step. Nobody measured this in people for this use, or the study that did measure it did not show it.
What would change this
A study in people, for this exact use, measuring this exact thing, that a reviewer signs off.
RNAWiki has not yet published a reviewed conclusion for this use.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Prednisolone are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
Every line above can be traced to the study named beside it. Follow the link and read it.
Bell’s palsy: 83.0% recovered against 63.6%, in a placebo-controlled trial
In plain words
This is the cleanest result the drug has. Patients with sudden one-sided facial paralysis were randomly given prednisolone, an antiviral, both or dummy tablets within three days of onset. Four in five on prednisolone had full facial function back at three months. Fewer than two in three did without it. The antiviral did nothing.
What was measured
Complete recovery of facial function on the House-Brackmann scale at 3 and 9 months, against placebo
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
A double-blind, placebo-controlled, factorial trial recruited 551 patients within 72 hours of symptom onset and assessed final outcomes in 496. Recovery of facial function on the House-Brackmann scale at 3 months was 83.0% with prednisolone against 63.6% without it (P<0.001), and at 9 months 94.4% against 81.6% (P<0.001). Acyclovir showed no benefit alone (71.2% against 75.7%, adjusted P=0.50) and added nothing to prednisolone. There were no serious adverse events in any group.
Written into the record, not signed off as a reviewed claim
Early rheumatoid arthritis: joint erosion nearly stopped over two years
In plain words
This one measured damage on X-rays rather than how patients felt. Over two years, hands in the prednisolone group barely changed. Hands in the placebo group visibly eroded. It is the trial that established a glucocorticoid can alter the course of the disease and not only its symptoms.
What was measured
Radiographic Larsen index progression and new erosion formation over two years, against placebo
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
A randomised, double-blind trial gave 128 adults with rheumatoid arthritis of less than two years’ duration either oral prednisolone 7.5 mg daily or placebo for two years, alongside their other treatment; radiographic analysis was based on 106 patients with films at baseline and two years. Larsen index scores rose by a mean of 0.72 units on prednisolone against 5.37 units on placebo (P=0.004). Of 147 hands with no erosions at baseline, 22.1% in the prednisolone group and 45.6% in the placebo group had acquired erosions at two years — a difference of 23.5 percentage points (95% CI 5.9 to 40.7, P=0.007). There was no difference between groups in the acute-phase response.
Written into the record, not signed off as a reviewed claim
STOPAH: the alcoholic hepatitis indication missed its primary endpoint
In plain words
Prednisolone had been recommended for severe alcoholic hepatitis for decades. The definitive trial randomised more than a thousand patients and found a survival benefit at 28 days that did not reach statistical significance, nothing at all at 90 days or a year, and nearly twice the rate of serious infection.
What was measured
All-cause mortality at 28 days, 90 days and 1 year, against matched placebo
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
STOPAH was a multicentre, double-blind, 2-by-2 factorial trial in 1,103 patients with severe alcoholic hepatitis, with primary-endpoint data from 1,053. Mortality at 28 days was 17% (45 of 269) on placebo-placebo, 14% (38 of 266) on prednisolone-placebo, 19% (50 of 258) on pentoxifylline-placebo and 13% (35 of 260) on both. The odds ratio for 28-day mortality with prednisolone was 0.72 (95% CI 0.52 to 1.01, P=0.06). There were no significant between-group differences at 90 days or at 1 year. Serious infections occurred in 13% of patients treated with prednisolone against 7% of those not treated with it (P=0.002).
Written into the record, not signed off as a reviewed claim
Preschool viral wheeze: no better than placebo in 687 children
In plain words
A five-day course of prednisolone was standard practice for small children brought to hospital wheezing with a cold. A trial of 700 of them found it did not shorten their stay in hospital, and did not improve a single secondary measure either.
What was measured
Duration of hospitalisation, against placebo
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
A randomised, double-blind, placebo-controlled trial in three English hospitals enrolled 700 children aged 10 to 60 months presenting with mild-to-moderate virus-induced wheeze; 687 were analysed (343 prednisolone, 344 placebo). Duration of hospitalisation was 13.9 hours on placebo against 11.0 hours on prednisolone, a ratio of geometric means of 0.90 (95% CI 0.77 to 1.05) — not significant. There was no significant difference in the Preschool Respiratory Assessment Measure, albuterol use, the 7-day symptom score, or the number of adverse events.
Written into the record, not signed off as a reviewed claim
PREDNOS: a longer course in childhood nephrotic syndrome changed nothing
In plain words
Earlier reviews had suggested that giving prednisolone for four months rather than two would keep childhood nephrotic syndrome from coming back. A properly blinded trial gave the extra fourteen weeks as real drug or as matching placebo. Relapse happened at the same rate either way.
What was measured
Time to first relapse over a minimum 24 months, extended against standard course
Effect estimate
No reviewed effect estimate exists for this record.
Limits
This entry records a failure.
From the source
PREDNOS randomised 237 children aged 1 to 14 with a first episode of steroid-sensitive nephrotic syndrome to an extended 16-week prednisolone course (total 3,150 mg/m2) or a standard 8-week course (total 2,240 mg/m2), with matching placebo so tablet counts were identical, across 125 UK hospitals. There was no significant difference in time to first relapse (hazard ratio 0.87, 95% CI 0.65 to 1.17, log-rank P=0.28), nor in frequently relapsing nephrotic syndrome (53% against 50%, P=0.75), steroid-dependent disease (42% against 44%, P=0.77) or need for other immunosuppression (54% against 56%, P=0.81).
Written into the record, not signed off as a reviewed claim
Even a short course carries a measurable harm signal
In plain words
A five-day course of steroids is treated as trivial. In a study of more than one and a half million American adults, the thirty days after such a course carried five times the rate of blood poisoning, three times the rate of blood clots and nearly twice the rate of fracture.
What was measured
Incidence rate ratios for sepsis, venous thromboembolism and fracture in the 30 days after a short oral corticosteroid course
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
A retrospective cohort and self-controlled case series across a nationwide United States private-insurance dataset covered 1,548,945 adults aged 18 to 64, of whom 327,452 (21.1%) received at least one outpatient prescription for a course of oral corticosteroid shorter than 30 days over three years. Within 30 days of initiation the incidence rate ratio was 5.30 (95% CI 3.80 to 7.41) for sepsis, 3.33 (2.78 to 3.99) for venous thromboembolism and 1.87 (1.69 to 2.07) for fracture, diminishing over the following 31 to 90 days. The increased risk persisted at prednisone-equivalent doses below 20 mg per day: 4.02 for sepsis, 3.61 for venous thromboembolism, 1.83 for fracture, all P<0.001. The commonest indications were upper respiratory infections, spinal conditions and allergies.
Written into the record, not signed off as a reviewed claim
The "steroid-equivalent dose" table is a potency conversion, not an outcome equivalence
In plain words
Every hospital has a chart saying that so many milligrams of one steroid equals so many of another. Those numbers came from measurements of anti-inflammatory potency in the 1950s and 1960s. They were never validated against clinical outcomes, and they do not carry over to bone loss, blood sugar or adrenal suppression, which follow the drug’s half-life rather than its potency.
What was measured
That the standard equivalence table lets one glucocorticoid be swapped for another with the same benefit and the same harm — it is a potency conversion built from anti-inflammatory bioassay, and half-life-driven harms do not follow it
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
Glucocorticoid equivalence tables derive from relative receptor affinity and from bioassays of anti-inflammatory activity, and rank prednisolone at roughly four times cortisol and dexamethasone at roughly 25 to 30 times cortisol. Duration of hypothalamic-pituitary-adrenal axis suppression tracks the biological half-life, which is 12 to 36 hours for prednisolone and 36 to 72 hours for dexamethasone, so equal anti-inflammatory doses do not produce equal adrenal suppression. Mineralocorticoid activity diverges further still: prednisolone retains a fraction of cortisol’s sodium-retaining effect and dexamethasone has essentially none. No randomised trial has shown that equivalent-dose substitution between glucocorticoids produces equivalent clinical outcomes, and the class has no head-to-head programme comparable to the one that exists for, say, the statins.
Source
United States prescribing information for prednisolone sodium phosphate oral solution (PEDIAPRED, NDA 019157) and for dexamethasone tablets, pharmacology sections
Role in the trial
Not matched to a registered study
Identity check
no open identity hold
Audit mark
contested
Review state
Written into the record, not signed off as a reviewed claim
From "steroids are safe at low dose" to "the threshold is lower than we thought"
In plain words
For decades a small daily dose was treated as effectively harmless. Two large observational analyses moved that line: bone density starts falling above five milligrams a day, and infection and clot risk rise even on short courses under twenty milligrams a day. The class did not become more dangerous; the measurement got better.
What was measured
That low-dose glucocorticoid therapy is free of meaningful harm — an inference from the absence of measurement, which two large analyses have now filled in
Effect estimate
No reviewed effect estimate exists for this record.
Limits
See the technical detail.
From the source
A meta-analysis of 66 bone-mineral-density papers and 23 fracture papers found strong correlations between cumulative dose and bone loss and between daily dose and fracture risk, with fracture risk rising within 3 to 6 months of starting and falling after stopping, independent of underlying disease, age and sex; it identified more than 5 mg daily of prednisolone or equivalent as the threshold for measurable bone loss. The 2017 nationwide cohort then showed the sepsis, thromboembolism and fracture signal persisted below a 20 mg prednisone-equivalent daily dose in short courses. Both are observational, and confounding by indication is the standing objection: sicker people get more steroid. The self-controlled case series design in the second study, which compares each person with themselves, is the response to that objection rather than a refutation of it.
This order is fixed in code and does not count clicks or time on the page.
What is not here
5 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
The older medicine-wide conclusion held in this record
Written for a clinical reader, and about the medicine as a whole rather than about one indication, population and set of trials. RNAWiki does not treat it as a programme conclusion and no reviewer has signed it off in that form. It is here word for word because it is what the record holds.
A synthetic cortisol that binds the glucocorticoid receptor in nearly every cell and switches off the genes that make inflammatory signals — 83.0% of patients recovered facial function by three months in the Bell’s palsy trial against 63.6% without it (p<0.001), and in the largest alcoholic hepatitis trial ever run it missed its primary endpoint with an odds ratio for 28-day mortality of 0.72 (95% CI 0.52 to 1.01, p=0.06) while doubling serious infections.
Recorded evidence blocks (12)
Q2
What did Prednisolone's largest trial (6000000 people) and its longest (25 years) measure?
6000000 people in Prednisolone's largest registered study, 25 years in its longest registered window, measuring Mortality resulting from treatment, underlying disease, or unrelated causes. ClinicalTrials.gov · 2026-09-01
208 phase2, 204 phase3, 139 phase4, 74 na, 59 phase1, 19 na or unstated, 5 early phase1; NCT00268476; 2030-12. Last human test completed 2026, NCT06919458.
Interpretation These counts include studies where Prednisolone was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.
Show the evidence
phase2
208
phase3
204
phase4
139
na
74
phase1
59
na or unstated
19
2 more recorded rows
early phase1
5
Last recorded human testNCT06919458
2026-08-15
recorded 2026-09-01 · last checked 2026-09-04
Q3
From mouse to human: where has Prednisolone shown lifespan?
"Recommended by DSMB due to lack of accrual"; 83 of 645 registered studies
Show the evidence
Trial
NCT00230035
withdrawn; "Recommended by DSMB due to lack of accrual"
NCT00275106
terminated; "Withdrawn due to an excess of toxic deaths"
NCT00306670
terminated; "Sponsor no longer funding study."
NCT00327197
terminated; "The study was truncated due to the long period of enrollment and the collection of a sufficient amount of data that allowed the scientific objectives to be met"
NCT00331058
terminated; "The study was truncated due to the long period of enrollment and the collection of a sufficient amount of data that allowed the scientific objectives to be met"
NCT00332839
terminated; "The trial was terminated early due to slow enrollment. It was determined that the planned sample size of 300 could not be achieved."
14 further recorded trials
NCT00354198
terminated; "short of participants"
NCT00425438
terminated; "Study was terminated early for administrative reasons."
NCT00430677
terminated; "Terminated due to failure to meet the primary efficacy endpoint in the Short-term Period"
NCT00478036
terminated; "insufficient enrollment"
NCT00521989
terminated; "CRx-102-006 study results, negative"
NCT00539799
withdrawn; "Local pharmacy unwilling to comply with study protocol"
NCT00573157
terminated; "The study was terminated due to unanticipated safety issues"
NCT00596947
terminated; "due to low study enrollment"
NCT00626197
terminated; "Study was terminated due to an imbalance of serious and opportunistic infections in the ocrelizumab treated patients versus the placebo arm."
NCT00637832
terminated; "no information"
NCT00796250
terminated; "Due to poor patient recruitment, a decision was made to terminate this trial."
NCT00798616
withdrawn; "We were unable to enroll a sufficient number of patients due to manpower."
NCT00799773
terminated; "Low enrollment rate"
NCT00953771
terminated; "low enrollment"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Prednisolone used Prednisolone acetate ophthalmic suspension 1% — over how long?
Which of 50 improvement of basdai after 14 days of treatment, admission to the intensive care and adverse drug effects did Prednisolone's trials measure?
50 improvement of basdai after 14 days of treatment, admission to the intensive care and adverse drug effects lead 40 outcome terms across Prednisolone's trials. ClinicalTrials.gov · 2026-09-01
event free survival at 3 4 years after diagnosis, toxicity, renal function, an acr20 response, disease free survival by routine imaging and glomerular filtration rate from baseline to month 12 follow.
Show the evidence
event free survival
1
event free survival after first randomization
1
disease free survival after second and third randomization
1
event free survival at 3 4 years after diagnosis
1
toxicity
1
renal function
1
14 more recorded rows
an acr20 response
1
disease free survival by routine imaging
1
glomerular filtration rate from baseline to month 12
1
rate of complete remission
1
disease free survival
1
proteinuria
1
side effects
1
renal function at month 12 post transplantation
1
creatinine clearance rate
1
remission rate
1
remission duration
1
overall survival
1
therapeutic failure rate
1
50 improvement of basdai after 14 days of treatment
1
recorded 2026-09-01 · last checked 2026-09-04
Q7
Which of Prednisolone's 118 ongoing trials reports first?
Overall survival; Number of exacerbations; latest 2038-09-30
Show the evidence
Trial
NCT00268476
"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy"; n 11992; "Overall survival"; 2030-12
NCT00555607
"Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease"; n 233; "Number of exacerbations"; 2026-12
NCT01059786
"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia"; n 69; "Number of Participants Receiving Pentostatin + Rituximab and Bendamustine + Rituximab Who Achieve a Complete Remission (CR) + Partial Response (PR)"; 2031-06-30
NCT01920932
"Adcetris (Brentuximab Vedotin), Combination Chemotherapy, and Radiation Therapy in Treating Younger Patients With Stage IIB, IIIB and IV Hodgkin Lymphoma"; n 77; "Percentage of Initially Enrolled Patients That Have a Complete Response at Early Response Assessment Compared to Historical Control"; 2028-05
NCT02889523
"Study of Tazemetostat in Newly Diagnosed Diffuse Large B Cell and Follicular Lymphoma Patients Treated by Chemiotherapy"; n 214; "Phase I : Number of Dose Limiting Toxicities"; 2029-09
NCT02936505
"Clinical Study Evaluating Two Treatment Protocols for Immunosuppressive Drugs. Looking at 3-year Incidence of CLAD."; n 249; "Number of patients with incidence of CLAD"; 2026-10-30
14 further recorded trials
NCT03007147
"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia"; n 352; "Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)"; 2027-08-14
NCT03117751
"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma"; n 790; "Event-free survival of ALL patients (EFS)"; 2028-09-30
NCT03165734
"A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis"; n 407; "Spleen volume"; 2028-10-13
NCT03206671
"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents"; n 650; "Event-free survival (EFS)"; 2027-06
NCT03286634
"ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016"; n 60; "Event Free Survival"; 2033-03-31
NCT03292861
"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients"; n 60; "Percentage of Participants With Composite Efficacy Failure at 12 Months"; 2026-03-31
NCT03415828
"Ethanol Gel Versus Steroid in Refractory Lumbar Discogenic Pain"; n 230; "Short-term efficacy profile"; 2027-05-29
NCT03418779
"Treatment Effects of Chinese Medicine (Yi-Qi-Qing-Jie Herbal Compound) Combined With Immunosuppression Therapies in IgA Nephropathy Patients With High-risk of ESRD"; n 60; "First occurrence of 40% decrease in eGFR from baseline"; 2024-12-31
NCT03643276
"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017"; n 5000; "Event-free survival"; 2028-07-14
NCT03755804
"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17"; n 232; "Response rate of adequate response"; 2028-07-01
NCT03775460
"Methotrexate and Prednisolone Study in Erythema Nodosum Leprosum"; n 550; "Proportion of individuals free from Erythema Nodosum Leprosum (ENL) flares in 24 weeks"; 2025-10-01
NCT03781700
"Evaluation of Cortisone Treatment in Children With Acute Facial Nerve Palsy"; n 500; "House-Brackmann scale"; 2026-12-31
NCT03899337
"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome"; n 72; "Randomised Component - Progression free survival (PFS)"; 2028-07-31
NCT03902912
"Effect of Prednisolone Treatment on Uterine Natural Killer Cells"; n 84; "the number of uNK cells"; 2028-04-30
recorded 2026-09-01 · last checked 2026-09-04
Q8
Which running trial of Prednisolone could settle lifespan?
NCT06751108 measures Overall survival, reading out 2025-06-30.
30 open trials; n 2000; "Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients"
Show the evidence
Trial
NCT06751108
"Impact of Concomitant Use of Steroids and Immune-Checkpoint Inhibitors on Survival Outcomes in NSCLC Patients"; n 2000; "Overall survival"; 2025-06-30
NCT04759586
"Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma"; n 244; "Progression-free survival (PFS)"; 2026-12-31
NCT04862221
"TReatment for ImmUne Mediated PathopHysiology"; n 44; "Survival with native liver (SNL)"; 2027-02
NCT07553988
"A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer"; n 120; "Median Progression-free survival (PFS) at 1 year in RS-113 treatment arms"; 2027-05-09
NCT03206671
"Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents"; n 650; "Event-free survival (EFS)"; 2027-06
NCT03007147
"Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia"; n 352; "Disease free survival (DFS) of Randomized Arms (standard risk [SR] Philadelphia chromosome [Ph+] acute lymphoblastic leukemia [ALL] patients)"; 2027-08-14
14 further recorded trials
NCT07571681
"Colchicine for Autoimmune and Subacute Thyroiditis"; n 300; "Mean Change in C-Reactive Protein (CRP)"; 2027-09
NCT03914625
"A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia"; n 6720; "Disease free survival (DFS) in randomization eligible patients with higher risk features (SR-High) or standard risk average (SR-Avg) B-ALL patients based on randomization with addition of blinatumomab"; 2027-09-30
NCT07227428
"Comparison of Glucocorticoid Tapering Schedules in Rheumatoid Arthritis"; n 206; "Disease Activity Score 28-CRP"; 2027-12-31
NCT07252271
"Very Low Dose Prednisolone on Newly Diagnosed Rheumatoid Arthritis"; n 112; "the change of DAS28-CRP at 4 weeks comparing prednisolone group and placebo group."; 2028-06-30
NCT03643276
"Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017"; n 5000; "Event-free survival"; 2028-07-14
NCT03899337
"A Trial of CHOP-R Therapy, With or Without Acalabrutinib, in Patients With Newly Diagnosed Richter's Syndrome"; n 72; "Randomised Component - Progression free survival (PFS)"; 2028-07-31
NCT06143891
"A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease."; n 260; "Event-Free Survival (EFS)"; 2028-09-29
NCT03117751
"Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma"; n 790; "Event-free survival of ALL patients (EFS)"; 2028-09-30
NCT06472219
"PREDICATE Trial For Respiratory Tract Infections"; n 1300; "30-day all-cause sepsis or all-cause mortality"; 2028-12-08
NCT06188676
"Multicenter Study of Safety and Efficacy Nivolumab at the Fixed Dose 40 mg (Nivo40) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed PMBL"; n 100; "Progression-free survival (PFS)"; 2029-04-01
NCT07775235
"Treatment Response in Immune-mediated Myositis Associated Rapidly-progressing Interstitial Lung Disease"; n 80; "All-cause mortality at 6 months from treatment initiation"; 2029-07-01
NCT06336395
"Ma-Spore ALL 2020 Study"; n 500; "Overall survival (OS)"; 2030-03
NCT06585774
"A Study to Evaluate Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease"; n 240; "Event Free Survival (EFS)"; 2030-03-31
NCT00268476
"Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy"; n 11992; "Overall survival"; 2030-12
Q9
Which 181 trials of Prednisolone posted no result?
Posted no result
181 of 181 completed trials
Registrations
NCT00004430, NCT00002576, NCT00518375, NCT00518271, NCT00057421 and NCT00311961, and 175 more
Completion dates
oldest 1998-09; newest 2024-08-13
Show the evidence
Trial
NCT00004430
1998-09
NCT00002576
2001-01
NCT00518375
2001-05
NCT00518271
2002-06
NCT00057421
2002-09
NCT00311961
2003-08
14 further recorded trials
NCT00261820
2005-01
NCT00170729
2005-02-28
NCT00312520
2005-06
NCT00312325
2005-08
NCT00198523
2005-10
NCT00003421
2005-11
NCT00384306
2006-01
NCT00885820
2006-01
NCT00048152
2006-03
NCT00380133
2006-04
NCT00337623
2006-07
NCT00753103
2006-07
NCT00134693
2006-08-03
NCT00135122
2007-01
Q10
At the median, Prednisolone's trials enrolled 80 people — anything larger?
Median enrolment
80
Largest enrolment
6000000
Registered trials counted
633
Q11
What do 28066 spontaneous reports say about Prednisolone — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Prednisolone appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 28066 reaction mentions were counted: neutropenia 5374; febrile neutropenia 4674; rheumatoid arthritis 4237; pemphigus 2586. open-targets-adr · CHEMBL131 · 2026-06-24
Was Prednisolone studied with fasting and exercise?
fasting and exercise are named in Prednisolone's label sentences: "This study paves the way to trial even lower doses of prednisolone once daily in patients fasting for Ramadan with AI." openfda-label+europepmc · 2023-11-29
2 recorded statements; fasting, exercise
Show the evidence
fasting
This study paves the way to trial even lower doses of prednisolone once daily in patients fasting for Ramadan with AI.
exercise
However, to date no randomized controlled trial has directly compared the efficacy of exercise and oral corticosteroids.
recorded 2023-11-29 · last checked 2026-09-04
Q13
What is recorded about Prednisolone and mTOR?
"From the 257 KTRs studied, 81 KTRs had their immunosuppressive agents switched from tacrolimus-MPA-prednisolone immunosuppressive regimen, with majority (96.3%, n = 78) switching to everolimus, an mTOR inhibitor in combination with low-dose tacrolimus." — where Prednisolone and mTOR appear together. Europe PMC · pathway abstract search · 2025-09-08
"From the 257 KTRs studied, 81 KTRs had their immunosuppressive agents switched from tacrolimus-MPA-prednisolone immunosuppressive regimen, with majority (96.3%, n = 78) switching to everolimus, an mTOR inhibitor in combination with low-dose tacrolimus."
AMPKPMID 32997729
"In this study, we aimed to determine whether prednisolone (PD) attenuates adriamycin (ADR)-induced VSMC senescence and inflammation through the SIRT1-AMPK signaling pathway."
sirtuin
PMID 32997729
"In this study, we aimed to determine whether prednisolone (PD) attenuates adriamycin (ADR)-induced VSMC senescence and inflammation through the SIRT1-AMPK signaling pathway."
PMID 32270742
"Treatment with prednisolone, in combination with theophylline, curcumin or resveratrol increases SIRT1 expression, restores steroid sensitivity, and inhibits pro-inflammatory cytokine production from these cells and may reduce systemic inflammation in COPD. <i>The reviews of this paper are available via the supplemental material section.</i>"
mTOR
PMID 37200246
"Among 2,099 patients in follow-up, fifty-one (2.4%) were converted median 6.2 years after LTx to a CNI-free regimen combining mTOR inhibitors with prednisolone and an antimetabolite, two patients were switched to mTOR inhibitors with prednisolone only."
PMID 38655204
"We analyzed the impact of mTOR inhibitors sirolimus (SIR/S) and everolimus (EVR/E), calcineurin inhibitor tacrolimus (TAC/T), purine synthesis inhibitor mycophenolic acid (MPA/M), glucocorticoid prednisolone (PRE/P) and common double (T+S/E/M/P) and triple (T+S/E/M+P) combinations on antiviral T-cell functionality."
autophagy
PMID 30632520
"CONCLUSIONS Fangchinoline inhibits apoptosis of osteoblasts and protects against bone loss in prednisolone-induced osteoporosis rats by inducing autophagy."
PMID 25700544
"To address this possibility, we compared the impact of prednisolone administration on the skeletons of adult mice in which autophagy was suppressed in osteocytes, via deletion of Atg7 with a Dmp1-Cre transgene, to their control littermates."
PMID 26993765
"Glucocorticoid prednisolone induced both activation and degradation of GR, as well as autophagy in synovial fibroblasts."
recorded 2025-09-08 · last checked 2026-09-04
Where it is registeredIdentifiers, relations and other names
ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 11 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.